- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03101280
A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer
A Phase IB Combination Study of Rucaparib (CO-338) and Atezolizumab (MPDL3280A) in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Victoria
-
Melbourne, Victoria, Australia, 3000
- Peter MacCallum Cancer Centre
-
-
-
-
-
Lyon, France, 69008
- Centre Léon Berard
-
Pierre Benite, France, 69310
- Centre Hospitalier Lyon Sud; Service d'Oncologie Médicale
-
Villejuif CEDEX, France, 94800
- Gustave Roussy
-
-
-
-
-
Barcelona, Spain, 08035
- Hospital Universitario Vall d'Hebron
-
Madrid, Spain
- La Paz University Hospital
-
-
Navarra
-
Pamplona, Navarra, Spain, 31620
- Clinica Universidad de Navarra
-
-
-
-
-
London, United Kingdom, SW3 6JJ
- Royal Marsden Hospital - London
-
London, United Kingdom, WC1E 6AU
- University College London Hospitals NHS Foundation Trust - University College Hospital
-
Preston, United Kingdom, PR2 9HT
- Lancashire Teaching Hospitals NHS Foundation Trust
-
Sutton, United Kingdom, SM2 5PT
- Royal Marsden NHS Foundation Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- A life expectancy of at least 3 months
- Have disease that is measurable as according to RECIST v1.1
- Have sufficient archival formalin-fixed paraffin-embedded (FFPE) tumor tissue available for planned analyses
- For Part 1, have a histologically confirmed diagnosis of ovarian or endometrial cancer, and have received at least one line of prior therapy for metastatic disease
- For Part 2 ONLY, have disease that can be safely biopsied
- For Part 2 ONLY, have a deleterious germline or somatic breast cancer susceptibility gene 1 (BRCA1) or BRCA2 mutation or tumors that are wild-type BRCA but show high levels of loss of heterozygosity (LOH) (tBRCAwt/LOHhigh) signature
- For Part 2 Cohort 1 (ovarian cancer), high-grade serous or Grade 3 endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer (PPC)
- For Part 2 Cohort 1, have received at least one and no more than two lines of prior platinum-containing therapy and progressed after the most recent platinum therapy in a platinum-sensitive timeframe
- For Part 2 ONLY, Cohort 1, have a CA125 measurement that is greater than 2 times the upper limit of normal (ULN)
- For Part 2 Cohort 2 (TNBC), metastatic, histologically confirmed estrogen receptor (ER)-negative, progesterone receptor-negative, and HER2-negative adenocarcinoma of the breast per local laboratory assessment
- For Part 2 Cohort 2, radiologic/objective evidence of recurrence or disease progression after one line of chemotherapy for TNBC in the metastatic setting
- Have adequate organ function
Exclusion Criteria:
- History of prior malignancy except a) curatively treated non-melanoma skin cancer, b) solid tumor treated curatively more than 3 years ago without evidence of recurrence, c) For Cohort 1 (ovarian cancer): breast cancer with no evidence of disease or inactive for at least 3 years, and d) synchronous endometrial cancer (Stage 1A) with ovarian cancer
- Treatment with chemotherapy, radiation, hormones (except corticosteroids and megestrol acetate), or other anticancer therapies less than or equal to (<=) 14 days prior to first dose of study treatment
- Preexisting duodenal stent and/or any gastrointestinal disorder or defect that would, in the opinion of the investigator, interfere with absorption of rucaparib
- Symptomatic and/or untreated central nervous system metastases
- Prior treatment with any poly adenosine diphosphate-ribose polymerase (PARP) inhibitor
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose-Finding Phase (Part 1): Rucaparib and Atezolizumab
Approximately 6-18 participants with advanced gynecological cancers will receive different doses of rucaparib administered orally (PO) twice daily (BID) with a fixed dose of atezolizumab (1200 milligrams [mg] intravenously [IV], every 21 days) in 21-day cycles, starting with 400 mg rucaparib BID.
The recommended Phase II dose (RP2D), determined by the highest dose level with an acceptable safety profile and with a minimum of 6 participants at which fewer than one-third of participants experience a DLT, was identified as 600 mg rucaparib twice a day (BID).
|
Atezolizumab 1200 mg (equivalent to an average body weight-based dose of 15 milligrams per kilogram [mg/kg]) will be administered by IV infusion once every 3 weeks, corresponding to a 21-day treatment cycle.
Participants will receive atezolizumab starting on Cycle 1, Day 1. Participants deriving clinical benefit will be allowed to continue on study treatment until the absence of unacceptable toxicity or compelling evidence of disease progression.
Other Names:
The starting dosage level of rucaparib for Part 1 is 400 mg PO BID during a 21-day treatment cycle.
During Part 1, the rucaparib doses were increased up to a maximum of 600 mg PO BID using a standard 3 + 3 dose escalation.
RP2D was identified as 600 mg BID.
During Part 2 of the study, rucaparib will be dosed at the RP2D determined in Part 1. Participants in Part 1 of the study will receive rucaparib starting on Cycle 1, Day 1.
During Part 2, participants will receive rucaparib monotherapy during a 21-day run-in period.
After completion of the rucaparib run-in period and the first on-treatment biopsy between Days 15 and 21 of the run-in period, participants will begin Cycle 1, Day 1 of the rucaparib.
Participants deriving clinical benefit will be allowed to continue on study treatment until the absence of unacceptable toxicity or compelling evidence of disease progression.
Other Names:
|
Experimental: Dose-Expansion Phase (Part 2): Rucaparib and Atezolizumab
Two tumor-specific expansion cohorts will begin treatment with a 21-day run-in period of rucaparib monotherapy at the specified dose for rucaparib in the potential RP2D identified in Part 1 for the combination. Cohort 1 will have approximately 30 participants with advanced, platinum-sensitive ovarian cancer with tumors harboring a tBRCA mutation [tBCRA(mut)] or BRCA-like molecular signature [tBRCA(wt)/LOH(high)]. Cohort 2 will have approximately 20 participants with previously treated triple-negative breast cancer (TNBC) with a tBRCA mutation [tBCRA(mut)] or BRCA-like molecular signature [tBRCA(wt)/LOH(high)] and have not been exposed to cancer immunotherapies. Following the run in period, participants will receive the combination of rucaparib (specified dose, BID) and atezolizumab (1200 mg IV, every 21 days) in 21-day cycles. |
Atezolizumab 1200 mg (equivalent to an average body weight-based dose of 15 milligrams per kilogram [mg/kg]) will be administered by IV infusion once every 3 weeks, corresponding to a 21-day treatment cycle.
Participants will receive atezolizumab starting on Cycle 1, Day 1. Participants deriving clinical benefit will be allowed to continue on study treatment until the absence of unacceptable toxicity or compelling evidence of disease progression.
Other Names:
The starting dosage level of rucaparib for Part 1 is 400 mg PO BID during a 21-day treatment cycle.
During Part 1, the rucaparib doses were increased up to a maximum of 600 mg PO BID using a standard 3 + 3 dose escalation.
RP2D was identified as 600 mg BID.
During Part 2 of the study, rucaparib will be dosed at the RP2D determined in Part 1. Participants in Part 1 of the study will receive rucaparib starting on Cycle 1, Day 1.
During Part 2, participants will receive rucaparib monotherapy during a 21-day run-in period.
After completion of the rucaparib run-in period and the first on-treatment biopsy between Days 15 and 21 of the run-in period, participants will begin Cycle 1, Day 1 of the rucaparib.
Participants deriving clinical benefit will be allowed to continue on study treatment until the absence of unacceptable toxicity or compelling evidence of disease progression.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of Participants With Adverse Events
Time Frame: Baseline up to approximately 45 months
|
Baseline up to approximately 45 months
|
Percentage of Participants With Dose-Limiting Toxicities (DLTs) [Part 1]
Time Frame: Cycle 1 (Day 1 up to Day 21)
|
Cycle 1 (Day 1 up to Day 21)
|
Recommended Phase II Dose (RP2D) of Rucaparib for the Combination [Part 1]
Time Frame: Cycle 1 (Day 1 up to Day 21)
|
Cycle 1 (Day 1 up to Day 21)
|
Number of Dose Modifications due to Adverse Events [Part 2]
Time Frame: Baseline up to approximately 45 months
|
Baseline up to approximately 45 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of Participants With Objective Response of Complete Response (CR) or Partial Response (PR) as Determined by Investigator Assessment Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
Time Frame: Baseline until disease progression or death from any cause, whichever occurs first (assessed every 12 weeks up to approximately 45 months)
|
Baseline until disease progression or death from any cause, whichever occurs first (assessed every 12 weeks up to approximately 45 months)
|
Percentage of Participants With Objective Response of CR or PR as Determined by Investigator Assessment Using Immune-Modified RECIST Incorporating Immune-Response (Cancer Antigen 125 [CA125] Response) Considerations
Time Frame: Baseline until disease progression or death from any cause, whichever occurs first (assessed every 12 weeks up to approximately 45 months)
|
Baseline until disease progression or death from any cause, whichever occurs first (assessed every 12 weeks up to approximately 45 months)
|
Duration of Response (DOR) as Determined by Investigator Assessment Using RECIST v1.1
Time Frame: Baseline until disease progression or death from any cause, whichever occurs first (assessed every 12 weeks up to approximately 45 months)
|
Baseline until disease progression or death from any cause, whichever occurs first (assessed every 12 weeks up to approximately 45 months)
|
DOR as Determined by Investigator Assessment Using Immune-Modified RECIST Incorporating Immune-Response (CA125 Response) Considerations
Time Frame: Baseline until disease progression or death from any cause, whichever occurs first (assessed every 12 weeks up to approximately 45 months)
|
Baseline until disease progression or death from any cause, whichever occurs first (assessed every 12 weeks up to approximately 45 months)
|
Progression-Free Survival (PFS) as Determined by Investigator Assessment Using RECIST v1.1
Time Frame: Baseline until disease progression or death from any cause, whichever occurs first (assessed every 12 weeks up to approximately 45 months)
|
Baseline until disease progression or death from any cause, whichever occurs first (assessed every 12 weeks up to approximately 45 months)
|
PFS as Determined by Investigator Assessment Using Immune-Modified RECIST Incorporating Immune-Response (CA125 Response) Considerations
Time Frame: Baseline until disease progression or death from any cause, whichever occurs first (assessed every 12 weeks up to approximately 45 months)
|
Baseline until disease progression or death from any cause, whichever occurs first (assessed every 12 weeks up to approximately 45 months)
|
Overall Survival
Time Frame: Baseline until Death (up to 45 months)
|
Baseline until Death (up to 45 months)
|
Steady State Maximum Plasma Concentration Observed (Cmax) for Rucaparib [Part 1]
Time Frame: Predose (0 hours [hrs]) on Day 1 of Cycles 1-4; 0, 0.5, 1, 1.5, 2.5, 4, 6, 8 hrs postdose on Day 15 of Cycle 1; at 30 days after the last dose of study treatment (up to 45 months; cycle length=21 days)
|
Predose (0 hours [hrs]) on Day 1 of Cycles 1-4; 0, 0.5, 1, 1.5, 2.5, 4, 6, 8 hrs postdose on Day 15 of Cycle 1; at 30 days after the last dose of study treatment (up to 45 months; cycle length=21 days)
|
Time to Maximum Plasma Concentration (tmax) for Rucaparib [Part 1]
Time Frame: Predose (0 hrs) on Day 1 of Cycles 1-4; 0, 0.5, 1, 1.5, 2.5, 4, 6, 8 hrs postdose on Day 15 of Cycle 1; at 30 days after the last dose of study treatment (up to 45 months; cycle length=21 days)
|
Predose (0 hrs) on Day 1 of Cycles 1-4; 0, 0.5, 1, 1.5, 2.5, 4, 6, 8 hrs postdose on Day 15 of Cycle 1; at 30 days after the last dose of study treatment (up to 45 months; cycle length=21 days)
|
Area Under the Plasma Concentration-Time Curve (AUC) for Rucaparib [Part 1]
Time Frame: Predose (0 hrs) on Day 1 of Cycles 1-4; 0, 0.5, 1, 1.5, 2.5, 4, 6, 8 hrs postdose on Day 15 of Cycle 1; at 30 days after the last dose of study treatment (up to 45 months; cycle length=21 days)
|
Predose (0 hrs) on Day 1 of Cycles 1-4; 0, 0.5, 1, 1.5, 2.5, 4, 6, 8 hrs postdose on Day 15 of Cycle 1; at 30 days after the last dose of study treatment (up to 45 months; cycle length=21 days)
|
Apparent Clearance (CL/F) for Rucaparib [Part 1]
Time Frame: Predose (0 hrs) on Day 1 of Cycles 1-4; 0, 0.5, 1, 1.5, 2.5, 4, 6, 8 hrs postdose on Day 15 of Cycle 1; at 30 days after the last dose of study treatment (up to 45 months; cycle length=21 days)
|
Predose (0 hrs) on Day 1 of Cycles 1-4; 0, 0.5, 1, 1.5, 2.5, 4, 6, 8 hrs postdose on Day 15 of Cycle 1; at 30 days after the last dose of study treatment (up to 45 months; cycle length=21 days)
|
Minimum Plasma Concentration During the Dosing Interval (Cmin) for Rucaparib [Part 2]
Time Frame: Predose (0 hrs) on Day 1 of Cycles 1-4; at 30 days after the last dose of study treatment (up to 45 months; cycle length=21 days)
|
Predose (0 hrs) on Day 1 of Cycles 1-4; at 30 days after the last dose of study treatment (up to 45 months; cycle length=21 days)
|
Serum Concentration of Atezolizumab [Parts 1 and 2]
Time Frame: Predose (0 hrs) on Day 1 of Cycles 1-4, 8 and every 8 cycles (up to 45 months); 0.5 hrs postdose (infusion duration=30-60 minutes) on Day 1 of Cycles 1 and 3; at 30 and 120 days after last dose of study treatment (up to 45 months; cycle length=21 days)
|
Predose (0 hrs) on Day 1 of Cycles 1-4, 8 and every 8 cycles (up to 45 months); 0.5 hrs postdose (infusion duration=30-60 minutes) on Day 1 of Cycles 1 and 3; at 30 and 120 days after last dose of study treatment (up to 45 months; cycle length=21 days)
|
Number of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab
Time Frame: Baseline up to approximately 45 months
|
Baseline up to approximately 45 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Triple Negative Breast Neoplasms
- Genital Neoplasms, Female
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Poly(ADP-ribose) Polymerase Inhibitors
- Rucaparib
- Atezolizumab
Other Study ID Numbers
- WO39409
- 2016-002610-47 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gynecologic Neoplasms
-
Katja Haemmerli KellerUniversity of BernRecruiting
-
Canadian Cancer Trials GroupInnate PharmaCompleted
-
University Health Network, TorontoRecruiting
-
Washington University School of MedicineBarnes-Jewish HospitalCompletedGynecologic Oncology PatientUnited States
-
M.D. Anderson Cancer CenterPharmacia; LifeCellCompletedNeoplasms, GynecologicUnited States
-
University of Campania "Luigi Vanvitelli"CompletedBenign Gynecologic NeoplasmItaly
-
Federal University of Minas GeraisUnknownQuality of Life | Gynecologic Cancer | Palliative Care | Therapeutic Touch | Gynecologic Neoplasm | ReikiBrazil
-
Assiut UniversityUnknownBenign Gynecologic NeoplasmEgypt
-
University Hospital, Basel, SwitzerlandCompletedGynecologic Cancer | Gynecologic DiseaseSwitzerland
-
University of LouisvilleJames Graham Brown Cancer CenterCompleted
Clinical Trials on Atezolizumab
-
University of Southern CaliforniaNational Cancer Institute (NCI); Genentech, Inc.RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditionsUnited States
-
Yonsei UniversityNot yet recruitingNon-small Cell Lung CancerKorea, Republic of
-
Intergroupe Francophone de Cancerologie ThoraciqueRoche Pharma AG; GFPCCompletedSmall Cell Lung CancerFrance
-
First Affiliated Hospital of Zhejiang UniversityHoffmann-La Roche; Geneplus-Beijing Co. Ltd.UnknownNon-Small Cell Lung CancerChina
-
Incyte CorporationHoffmann-La Roche; Genentech, Inc.TerminatedUC (Urothelial Cancer) | NSCLC (Non-small Cell Lung Carcinoma)United States
-
Seoul National University HospitalUnknown
-
Astellas Pharma Global Development, Inc.CompletedAcute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) MutationUnited States
-
The Netherlands Cancer InstituteRoche Pharma AGCompletedBreast Cancer | Ovarian Cancer | Cervix Cancer | Endometrial CancerNetherlands
-
Yale UniversityTerminatedAsymptomatic MyelomaUnited States
-
Corvus Pharmaceuticals, Inc.Genentech, Inc.CompletedRenal Cell Cancer | Metastatic Castration Resistant Prostate CancerUnited States, Canada, Australia